Newbury Pharmaceuticals AB

NEWBRY · ST · Healthcare / Drug Manufacturers - Specialty & Generic

2.02SEK+0.01 (+0.50%)

Price History

Full chart

Market Stats

Previous Close2.01

Open2.01

Day Range1.99 – 2.02

52-Week Range0.76 – 3.47

Volume6.40K

Market Cap67.48M

P/E (TTM)0.00

Forward P/E0.00

EPS-0.78

Dividend Yield0.00%

Beta1.25

50-Day Avg2.50

200-Day Avg1.70

About

Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Karl Alexius Tiger Karlsson
Employees7
HeadquartersMedicon Village, Lund, Sweden, 223 81, Sweden
Websitehttps://www.newburypharma.com

Leadership

Mr. Karl Alexius Tiger KarlssonFounder, CEO & Director · b. 1974
Mr. Christoffer TellChief Financial Officer · b. 1987
Mr. Fredrik HellqvistGeneral Manager for Nordics · b. 1973

Financials

Income Statement

Currency: SEK	2021-08-31	2022-08-31	2023-08-31	2024-08-31	2025-08-31
Total Revenue	2.83M	5.52M	10.27M	36.83M	-
Growth (%)	-	+94.98%	+86.11%	+258.75%	-
Cost of Revenue	2.37M	3.95M	6.32M	20.80M	-
Gross Profit	460.00K	1.56M	3.95M	16.03M	-
Gross Margin	16.26%	28.35%	38.46%	43.53%	-
Operating Expense	6.08M	16.23M	23.54M	30.11M	-
Operating Income	-5.62M	-14.67M	-19.59M	-14.08M	-20.61M
Operating Margin	-198.69%	-265.90%	-190.79%	-38.23%	-
EBITDA	-4.91M	-13.66M	-18.33M	-12.14M	-16.28M
EBITDA Margin	-173.70%	-247.66%	-178.57%	-32.97%	-
Net Income	-5.56M	-14.67M	-19.43M	-15.40M	-20.61M
Net Income Margin	-196.43%	-265.90%	-189.28%	-41.83%	-
Interest Expense	35.00K	0	0	1.53M	1.65M
Interest Expense % of Total Revenue	1.24%	0.00%	0.00%	4.15%	-

Balance Sheet

Currency: SEK	2021-08-31	2022-08-31	2023-08-31	2024-08-31	2025-08-31
Total Assets	42.81M	86.91M	72.92M	90.87M	-
Total Liabilities	4.34M	18.14M	23.54M	38.95M	-
Total Equity	38.47M	68.77M	49.38M	51.92M	-
Cash	13.14M	33.33M	8.53M	15.30M	-
Net Debt	-13.14M	-33.33M	-8.53M	-15.30M	-

Cash Flow

Currency: SEK	2021-08-31	2022-08-31	2023-08-31	2024-08-31	2025-08-31
Operating Cash Flow	-4.07M	-15.00M	-23.23M	-23.71M	-
Investing Cash Flow	-26.73M	-24.40M	-862.00K	-2.95M	-
Financing Cash Flow	43.95M	59.59M	-717.00K	33.44M	-
Capital Expenditure	23.09M	24.40M	862.00K	2.91M	2.21M
Free Cash Flow	-27.15M	-39.40M	-24.09M	-26.62M	-14.58M
FCF to OCF	667.78%	262.64%	103.71%	112.27%	-

Key Statistics & Ratios

Market Cap67.48M

Enterprise Value55.24M

Trailing P/E0.00

Forward P/E0.00

Price / Sales1.93

Price / Book2.66

EPS-0.78

Book Value0.864

Revenue (TTM)35.02M

Gross Profit (TTM)9.62M

EBITDA-21.32M

Profit Margin-76.85%

Operating Margin-54.08%

Return on Equity-67.46%

Return on Assets-15.79%

Shares Outstanding30.40M

Shares Float6.73M

Beta1.25

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%